C
0.952
0.01 (0.64%)
| Previous Close | 0.946 |
| Open | 1.00 |
| Volume | 59,260 |
| Avg. Volume (3M) | 146,366 |
| Market Cap | 52,910,836 |
| Price / Earnings (Forward) | 0.770 |
| Price / Sales | 2.03 |
| Price / Book | 0.640 |
| 52 Weeks Range | |
| Earnings Date | 5 Sep 2025 - 19 Sep 2025 |
| Profit Margin | -66.10% |
| Operating Margin (TTM) | -81.69% |
| Diluted EPS (TTM) | -0.310 |
| Total Debt/Equity (MRQ) | 1.13% |
| Current Ratio (MRQ) | 10.25 |
| Operating Cash Flow (TTM) | -32.98 M |
| Levered Free Cash Flow (TTM) | -5.98 M |
| Return on Assets (TTM) | -12.47% |
| Return on Equity (TTM) | -18.66% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Connect Biopharma Holdings Limi | Bearish | Bearish |
AIStockmoo Score
1.0
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.00 |
|
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 40.65% |
| % Held by Institutions | 43.97% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Callan Capital, Llc | 31 Mar 2025 | 80,000 |
| Geowealth Management, Llc | 31 Mar 2025 | 0 |
| 52 Weeks Range | ||
| Median | 7.00 (635.06%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 12 Jun 2025 | 7.00 (635.06%) | Buy | 0.850 |
| 01 Apr 2025 | 8.00 (740.07%) | Buy | 0.572 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |